HomeCompareFDTKX vs MRK

FDTKX vs MRK: Dividend Comparison 2026

FDTKX yields 6.89% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FDTKX wins by $796.00 in total portfolio value
10 years
FDTKX
FDTKX
● Live price
6.89%
Share price
$14.53
Annual div
$1.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.5K
Annual income
$1,067.24
Full FDTKX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — FDTKX vs MRK

📍 FDTKX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFDTKXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FDTKX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FDTKX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FDTKX
Annual income on $10K today (after 15% tax)
$585.58/yr
After 10yr DRIP, annual income (after tax)
$907.15/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, FDTKX beats the other by $99.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FDTKX + MRK for your $10,000?

FDTKX: 50%MRK: 50%
100% MRK50/50100% FDTKX
Portfolio after 10yr
$31.1K
Annual income
$1,008.77/yr
Blended yield
3.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

FDTKX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FDTKX buys
0
MRK buys
0
No recent congressional trades found for FDTKX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFDTKXMRK
Forward yield6.89%3.25%
Annual dividend / share$1.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$31.5K$30.7K
Annual income after 10y$1,067.24$950.29
Total dividends collected$8.8K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FDTKX vs MRK ($10,000, DRIP)

YearFDTKX PortfolioFDTKX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,389$688.92$11,192$351.54+$197.00FDTKX
2$12,919$733.28$12,524$392.70+$395.00FDTKX
3$14,601$777.40$14,015$438.65+$586.00FDTKX
4$16,444$821.12$15,682$489.96+$762.00FDTKX
5$18,460$864.27$17,547$547.23+$913.00FDTKX
6$20,659$906.72$19,632$611.16+$1.0KFDTKX
7$23,053$948.35$21,963$682.53+$1.1KFDTKX
8$25,656$989.04$24,571$762.18+$1.1KFDTKX
9$28,480$1,028.69$27,486$851.08+$994.00FDTKX
10$31,541$1,067.24$30,745$950.29+$796.00FDTKX

FDTKX vs MRK: Complete Analysis 2026

FDTKXStock

The fund invests in a combination of Fidelity ® U.S. equity funds, international equity funds, bond funds, and short-term funds. The adviser allocates its assets according to a neutral asset allocation strategy shown in the glide path below that adjusts over time until it reaches an allocation similar to that of the Fidelity Freedom ® Income Fund, approximately 10 to 19 years after the year 2025.

Full FDTKX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this FDTKX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FDTKX vs SCHDFDTKX vs JEPIFDTKX vs OFDTKX vs KOFDTKX vs MAINFDTKX vs JNJFDTKX vs ABBVFDTKX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.